Results 201 to 210 of about 22,830 (226)

Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas

European Journal of Cancer, 2014
L, Karayan-Tapon, U, Cortes, P, Rivet, C, Jermidi, G, Vassal, M, Wager, L, Taillandier   +6 more
openaire   +2 more sources

Expanding the Roster of ROS1 Inhibitors

Journal of Clinical Oncology, 2017
Ibiayi, Dagogo-Jack, Alice T, Shaw
openaire   +2 more sources

ROS1-dependent cancers — biology, diagnostics and therapeutics

Nature Reviews Clinical Oncology, 2020
Alexander Drilon, Sudarshan Iyer, Adam Schoenfeld   +2 more
exaly  

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Annals of Oncology, 2019
Sai-Hong Ou, D R Camidge, G I Shapiro
exaly  

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma

Annals of Oncology, 2013
Hye Ryun Kim, S M Lim, R A Soo
exaly  

ROS1

1997
openaire   +1 more source

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

Annals of Oncology, 2015
Colin R Lindsay, J -C Soria, I Borget
exaly  

ROS1 fusions in Chinese patients with non-small-cell lung cancer

Annals of Oncology, 2013
K Fei
exaly  

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Proceedings of the National Academy of Sciences of the United States of America, 2015
Ted W. Johnson, Tod Smeal, Sergei Timofeevski   +2 more
exaly  

Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers

Modern Pathology, 2013
Yasuhito Arai, Tatsuhiro Shibata, Akihiko Yoshida   +2 more
exaly